osimertinib
Genecast to Evaluate Liquid Biopsy EGFR Mutation Test in Early-Stage Non-Small Cell Lung Cancer
The firm hopes its qPCR-based liquid biopsy test could help identify early-stage NSCLC patients eligible for adjuvant or neoadjuvant anti-EGFR TKI treatment.
In IMpower010, Tecentriq significantly reduced the risk of death or disease recurrence in patients with stage II to IIIA tumors, particularly in those with PD-L1 expression.
Between June 2019 and June 2020, regulatory authorities from participating countries approved 38 cancer drugs, 10 of which were for molecularly defined indications.
UK's MHRA Grants Early Access to AstraZeneca's Tagrisso as Adjuvant NSCLC Treatment
This is MHRA's first authorization under Project Orbis, an international regulatory collaboration the UK body joined in January to speed access to drugs.
AstraZeneca's Tagrisso Recommended by EMA Committee in Adjuvant NSCLC
The CHMP evaluated data showing the drug reduced the risk of disease recurrence or death by 80 percent in EGFR-mutated, stage Ib to IIIa NSCLC patients.